# Filing Detail

Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-24-094124
Filing Date
2024-08-08
Accepted
2024-08-08 16:44:41
Documents
56
Period of Report
2024-06-30

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | 10-Q | tpst-20240630.htm iXBRL | 10-Q | 1773364
2 | EX-31.1 | tpst-ex31_1.htm | EX-31.1 | 17882
3 | EX-31.2 | tpst-ex31_2.htm | EX-31.2 | 17845
4 | EX-32.1 | tpst-ex32_1.htm | EX-32.1 | 8535
| Complete submission text file | 0000950170-24-094124.txt |  | 6089518

Data Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
5 | XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT | tpst-20240630.xsd | EX-101.SCH | 864030
59 | EXTRACTED XBRL INSTANCE DOCUMENT | tpst-20240630_htm.xml | XML | 783517

Mailing Address 2000 SIERRA POINT PARKWAY SUITE 400 BRISBANE CA 94005
Business Address 2000 SIERRA POINT PARKWAY SUITE 400 BRISBANE CA 94005 415-798-8589
Tempest Therapeutics, Inc. (Filer) CIK: 0001544227 (see all company filings)

EIN.: 451472564 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-35890 | Film No.: 241189200
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)